<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04939467</url>
  </required_header>
  <id_info>
    <org_study_id>B-0409-104</org_study_id>
    <nct_id>NCT04939467</nct_id>
  </id_info>
  <brief_title>Dedicated Drug-Drug Interaction (DDI) Study in Healthy Volunteers</brief_title>
  <official_title>A Phase 1, Open-Label, Non-Randomized, Fixed Sequence Study to Evaluate the Steady-state Pharmacokinetics of BLD-0409, Nintedanib and Pirfenidone When Administered Concurrently in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Blade Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Blade Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1, Open-Label, Non-Randomized, Fixed Sequence Study to Evaluate the Steady-state&#xD;
      Pharmacokinetics of BLD-0409, Nintedanib and Pirfenidone when Administered Concurrently in&#xD;
      Healthy Volunteers&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, open-label study designed to determine the effect of BLD-0409 on the&#xD;
      PK of nintedanib and pirfenidone, all at steady state, and to evaluate the safety and&#xD;
      tolerability of BLD-0409 administered with either nintedanib or pirfenidone in healthy adult&#xD;
      volunteers&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 15, 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed drug concentration (Cmax)</measure>
    <time_frame>Up to 18 days</time_frame>
    <description>Estimated from plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of the maximum drug concentration (Tmax)</measure>
    <time_frame>Up to 18 days</time_frame>
    <description>Estimated from plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the drug concentration-time curve (AUC) as follows: Pirfenidone - AUC0-8 (Arm 1); Nintedanib - AUC0-12 (Arm 2); BLD-0409 - AUC0-24 (both arms).</measure>
    <time_frame>Up to 18 days</time_frame>
    <description>Estimated from plasma concentration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence, nature and severity of treatment-emergent adverse events (TEAEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 18 days</time_frame>
    <description>Safety and tolerability will be assessed based on the incidence, nature and severity of TEAEs and SAEs, and changes in safety laboratories, vitals and ECGs</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">86</enrollment>
  <condition>Drug Drug Interaction</condition>
  <arm_group>
    <arm_group_label>Pirfenidone &amp; BLD-0409</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following an overnight fast, subjects will be administered IP in a fixed sequence.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nintedanib &amp; BLD-0409</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following an overnight fast, subjects will be administered IP in a fixed sequence.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pirfenidone 267 mg Oral Tablet</intervention_name>
    <description>Fixed sequence use of active product, TID</description>
    <arm_group_label>Pirfenidone &amp; BLD-0409</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nintedanib 150 mg Oral Capsule</intervention_name>
    <description>Fixed sequence use of active product, BID</description>
    <arm_group_label>Nintedanib &amp; BLD-0409</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BLD-0409 750 mg Oral Tablet</intervention_name>
    <description>Fixed sequence use of active product, QD</description>
    <arm_group_label>Nintedanib &amp; BLD-0409</arm_group_label>
    <arm_group_label>Pirfenidone &amp; BLD-0409</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female participants 18-55 years of age (inclusive) at the time of signing the&#xD;
             ICF.&#xD;
&#xD;
          2. Participants must be in good general health, in the opinion of the investigator, with&#xD;
             no significant medical history, have no clinically significant abnormalities on&#xD;
             physical examination at Screening, and/or before administration of the initial dose of&#xD;
             IP.&#xD;
&#xD;
          3. Participants must have clinical laboratory values within normal ranges or &lt; 1.2 times&#xD;
             upper limit of normal (ULN) as specified by the testing laboratory, unless deemed not&#xD;
             clinically significant (NCS) by the investigator.&#xD;
&#xD;
          4. Body mass index (BMI) 18 to ≤ 30 kg/m2.&#xD;
&#xD;
          5. Female participants must use double barrier contraception and refrain from oocyte&#xD;
             donation from at least 28 days prior to Screening and for 90 days after last dose of&#xD;
             IP.&#xD;
&#xD;
          6. Male participants and female partners of male participants must agree to use highly&#xD;
             effective, double barrier contraception and refrain from sperm donation from first&#xD;
             dose of IP and for 90 days after last dose of IP.&#xD;
&#xD;
          7. Females of childbearing potential must have a negative serum pregnancy test at&#xD;
             Screening and a negative urine pregnancy test on Day -1. Females not of childbearing&#xD;
             potential must be surgically infertile or post-menopausal (defined as cessation of&#xD;
             regular menstrual periods for at least 12 months), confirmed by follicle-stimulating&#xD;
             hormone (FSH) level &gt;40 mIU/mL at Screening.&#xD;
&#xD;
          8. Participants must provide signed informed consent prior to study entry and have the&#xD;
             ability and willingness to attend and comply with the necessary visits at the study&#xD;
             site.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Recent (less than 6 weeks) wound, or presence of an ongoing non-healing skin wound.&#xD;
&#xD;
          2. Presence of any underlying physical or psychological medical condition that, in the&#xD;
             opinion of the investigator, would make it unlikely that the participant will complete&#xD;
             the study per protocol.&#xD;
&#xD;
          3. Known cardiac disease.&#xD;
&#xD;
          4. Active malignancy and/or history of malignancy in the past 5 years, with the exception&#xD;
             of completely excised non-melanoma skin cancer or low grade cervical intraepithelial&#xD;
             neoplasia.&#xD;
&#xD;
          5. Serious local or systemic infection within 1 month of Screening requiring antibiotic&#xD;
             treatment or history of recurrent infections.&#xD;
&#xD;
          6. Any acute illness within 30 days prior to Day 1.&#xD;
&#xD;
          7. Surgery, bone fracture or major musculoskeletal injury within the past 3 months prior&#xD;
             to the first IP administration determined by the investigator to be clinically&#xD;
             relevant.&#xD;
&#xD;
          8. Positive for human immunodeficiency virus (HIV) antibody or antigen.&#xD;
&#xD;
          9. Positive hepatitis C virus (HCV) antibody or positive hepatitis B surface antigen&#xD;
             (HBsAg).&#xD;
&#xD;
         10. Systolic blood pressure (BP) &gt; 150 mmHg or &lt; 90 mmHg or diastolic BP &gt;90 mmHg or &lt;50&#xD;
             mmHg at Screening with one repeat allowed per the investigator's discretion at&#xD;
             Screening and Day -1.&#xD;
&#xD;
         11. Heart rate &lt; 40 beats per minute (bpm) or &gt; 100 bpm at Screening.&#xD;
&#xD;
         12. Prolonged QT interval corrected by Fridericia's formula (QTcF) (&gt;450 ms for males and&#xD;
             &gt;470 ms for females), cardiac arrhythmia, or any clinically significant abnormality in&#xD;
             the resting ECG, as judged by the investigator.&#xD;
&#xD;
         13. All prescription and over-the-counter medications (including herbal medications),&#xD;
             except for contraceptives, are prohibited within 7 days prior to the first IP&#xD;
             administration and throughout the entire duration of the study.&#xD;
&#xD;
         14. All vaccines within 14 days prior to first IP administration and throughout the entire&#xD;
             duration of the study.&#xD;
&#xD;
         15. Administration of investigational product in another study within 30 days prior to the&#xD;
             first IP administration (except BLD-0409), or five half-lives, whichever is longer.&#xD;
&#xD;
         16. Significant weight loss or gain between Screening and first IP administration.&#xD;
&#xD;
         17. Blood donation or significant blood loss within 60 days prior to the first IP&#xD;
             administration.&#xD;
&#xD;
         18. Plasma donation within 7 days prior to the first IP administration.&#xD;
&#xD;
         19. Females who are pregnant or breastfeeding.&#xD;
&#xD;
         20. Diets that could alter metabolism (i.e., high protein, Slim Fast®, Nutrisystem®, etc.)&#xD;
             within 7 days prior first IP administration.&#xD;
&#xD;
         21. History or presence of alcohol or drug abuse within the 1 year prior to the first IP&#xD;
             administration, and unwillingness to be totally abstinent during the treatment period.&#xD;
&#xD;
         22. Positive urine drug screen/alcohol breath test at Day -1 (admission). Repeat urine&#xD;
             drug screens will be permitted for suspected false positive results.&#xD;
&#xD;
         23. Intake of alcohol or caffeine-containing products from 48 hours before first IP&#xD;
             administration through the EOS visit.&#xD;
&#xD;
         24. Active smokers and users of nicotine-containing products. Note, participants must&#xD;
             discontinue smoking/use of nicotine-containing products from 48 hours before first IP&#xD;
             administration through the EOS visit.&#xD;
&#xD;
         25. Failure to satisfy the investigator of fitness to participate for any other reason.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kimberly S Cruz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Advanced Pharma CR, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joyce Simpauco</last_name>
    <phone>(650) 278 4291</phone>
    <email>jsimpauco@blademed.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Advanced Pharma</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33147</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Advanced Pharma</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 17, 2021</study_first_submitted>
  <study_first_submitted_qc>June 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2021</study_first_posted>
  <last_update_submitted>October 24, 2021</last_update_submitted>
  <last_update_submitted_qc>October 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pirfenidone</mesh_term>
    <mesh_term>Nintedanib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

